首页> 美国卫生研究院文献>Springer Open Choice >Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance
【2h】

Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance

机译:促肾上腺皮质激素治疗儿童和年轻人的特发性肾病综合征:与当代相关的早期临床研究的系统综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adrenocorticotropic hormone (ACTH) as a treatment for proteinuria due to nephrotic syndrome (NS) has re-emerged over the last decade. Current clinical data are primarily limited to adults with treatment-resistant NS. Largely unknown to today’s clinicians is the existence of early clinical studies, following ACTH’s introduction in the late 1940s, showing sustained proteinuria response in idiopathic NS in predominantly pediatric, treatment-naïve patients. Before ACTH, patients suffered severe edema and high mortality rates with no reliable or safe treatment. ACTH dramatically altered NS management, initially through recognition of diuresis effects and then through sustained proteinuria remission. This review synthesizes early clinical literature to inform current NS patient management. We undertook a MEDLINE search using MeSH terms “adrenocorticotropic hormone” and “nephrotic syndrome,” with limits 1945–1965 and English. Sixty papers totaling 1137 patients were found; 14 studies (9 short-term, five long-term, N = 419 patients) met inclusion criteria. Studies were divided into two groups: short-term (≤28 days) and long-term (>5 weeks; short-term initial daily treatment followed by long-term intermittent)ACTH therapy and results were aggregated. An initial response, defined as a diuresis, occurred in 74 % of patients/treatment courses across nine short-term ACTH studies. Analyzed in eight of these studies, proteinuria response occurred in 56 % of patients/treatment courses. Across five long-term ACTH studies, proteinuria response was shown in 71 % of patients and was sustained up to 4.7 years following treatment. The inventory and re-evaluation of early clinical data broadens the evidence base of clinical experiences with ACTH for implementation of current treatment strategies and aiding the design of future studies.Electronic supplementary materialThe online version of this article (doi:10.1007/s40620-016-0308-3) contains supplementary material, which is available to authorized users.
机译:在过去的十年中,肾上腺皮质激素(ACTH)作为治疗肾病综合症(NS)引起的蛋白尿的治疗药物再次出现。当前的临床数据主要限于患有抗药性NS的成年人。在1940年代后期引入ACTH之后,今天的临床医生几乎不知道是否存在早期临床研究,该研究表明,以特发性NS为主的小儿,未经治疗的患者持续存在蛋白尿反应。在ACTH之前,患者遭受严重水肿和高死亡率,没有可靠或安全的治疗方法。 ACTH最初通过认识利尿作用,然后通过持续的蛋白尿缓解,极大地改变了NS的管理。这篇综述综合了早期临床文献,为当前的NS患者管理提供了信息。我们使用MeSH术语“肾上腺皮质激素”和“肾病综合症”(限1945–1965年)和英语进行了MEDLINE搜索。共发现60篇论文,共1137例患者。 14项研究(9项短期,5项长期,N = 419例患者)符合纳入标准。研究分为两组:短期(≤28天)和长期(> 5周;短期初始每日治疗,然后长期间歇性)ACTH治疗,并汇总结果。在九项短期ACTH研究中,有74%的患者/治疗过程发生了最初的反应,即利尿作用。在其中的八项研究中进行了分析,蛋白尿反应发生在56%的患者/治疗过程中。在五项长期ACTH研究中,蛋白尿反应在71%的患者中显示出来,并在治疗后持续长达4.7年。早期临床数据的清单和重新评估扩大了ACTH的临床经验证据基础,可用于实施当前的治疗策略并帮助将来的研究设计。电子补充材料本文的在线版本(doi:10.1007 / s40620-016- 0308-3)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号